# Nilotinib Roll-over Protocol for Patients in Novartis-sponsored Nilotinib Study and Benefiting From Nilotinib Treatment

> **NCT01863745** · PHASE2 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 15 (actual)

## Conditions studied

- Gastrointestinal Stromal Tumors

## Interventions

- **DRUG:** nilotinib

## Key facts

- **NCT ID:** NCT01863745
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-06-25
- **Primary completion:** 2023-10-02
- **Final completion:** 2023-10-02
- **Target enrollment:** 15 (ACTUAL)
- **Last updated:** 2024-08-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01863745

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01863745, "Nilotinib Roll-over Protocol for Patients in Novartis-sponsored Nilotinib Study and Benefiting From Nilotinib Treatment". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT01863745. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*